Pfizer Halts Ranbaxy's Diflucan Generic With Court Ruling

Law360, New York (March 12, 2004, 12:00 AM EST) -- The U.S. District Court in Washington, D.C. has upheld Pfizer’s six-month pediatric exclusivity for its top selling anti-fungal medicine, Diflucan.

The court’s decision keeps a generic version by Indian drugmaker Ranbaxy Laboratories Ltd. off the market until July 29.

The ruling came in response to a suit filed by the generic manufacturer Ranbaxy contending that its generic version of Diflucan was not subject to the exclusivity period for Pfizer's product.

A previous lawsuit brought by Pfizer against Ranbaxy for infringement of its patent for Diflucan was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.